182 related articles for article (PubMed ID: 21480310)
1. Combined treatment targeting HIF-1α and Stat3 is a potent strategy for prostate cancer therapy.
Reddy KR; Guan Y; Qin G; Zhou Z; Jing N
Prostate; 2011 Dec; 71(16):1796-809. PubMed ID: 21480310
[TBL] [Abstract][Full Text] [Related]
2. G-quartet oligonucleotides: a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis.
Jing N; Li Y; Xiong W; Sha W; Jing L; Tweardy DJ
Cancer Res; 2004 Sep; 64(18):6603-9. PubMed ID: 15374974
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells.
Manohar SM; Padgaonkar AA; Jalota-Badhwar A; Rao SV; Joshi KS
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):15-27. PubMed ID: 22083267
[TBL] [Abstract][Full Text] [Related]
4. A perylene derivative regulates HIF-1α and Stat3 signaling pathways.
Chen H; Guan Y; Yuan G; Zhang Q; Jing N
Bioorg Med Chem; 2014 Feb; 22(4):1496-505. PubMed ID: 24485121
[TBL] [Abstract][Full Text] [Related]
5. Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma.
Liu F; Wang P; Jiang X; Tan G; Qiao H; Jiang H; Krissansen GW; Sun X
Cancer Sci; 2008 Oct; 99(10):2055-61. PubMed ID: 19016766
[TBL] [Abstract][Full Text] [Related]
6. T40214/PEI complex: a potent therapeutics for prostate cancer that targets STAT3 signaling.
Weerasinghe P; Li Y; Guan Y; Zhang R; Tweardy DJ; Jing N
Prostate; 2008 Sep; 68(13):1430-42. PubMed ID: 18615483
[TBL] [Abstract][Full Text] [Related]
7. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
Verheul HM; Salumbides B; Van Erp K; Hammers H; Qian DZ; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2008 Jun; 14(11):3589-97. PubMed ID: 18519793
[TBL] [Abstract][Full Text] [Related]
8. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
Rocchi P; Beraldi E; Ettinger S; Fazli L; Vessella RL; Nelson C; Gleave M
Cancer Res; 2005 Dec; 65(23):11083-93. PubMed ID: 16322258
[TBL] [Abstract][Full Text] [Related]
9. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3.
Hellsten R; Johansson M; Dahlman A; Dizeyi N; Sterner O; Bjartell A
Prostate; 2008 Feb; 68(3):269-80. PubMed ID: 18163422
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides.
Weerasinghe P; Garcia GE; Zhu Q; Yuan P; Feng L; Mao L; Jing N
Int J Oncol; 2007 Jul; 31(1):129-36. PubMed ID: 17549413
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice.
Zhang X; Zhang J; Wang L; Wei H; Tian Z
BMC Cancer; 2007 Aug; 7():149. PubMed ID: 17683579
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-inducible factor-1 in human breast and prostate cancer.
Kimbro KS; Simons JW
Endocr Relat Cancer; 2006 Sep; 13(3):739-49. PubMed ID: 16954428
[TBL] [Abstract][Full Text] [Related]
13. Human hormone-refractory prostate cancers can harbor mutations in the O(2)-dependent degradation domain of hypoxia inducible factor-1alpha (HIF-1alpha).
Anastasiadis AG; Ghafar MA; Salomon L; Vacherot F; Benedit P; Chen MW; Shabsigh A; Burchardt M; Chopin DK; Shabsigh R; Buttyan R
J Cancer Res Clin Oncol; 2002 Jul; 128(7):358-62. PubMed ID: 12136249
[TBL] [Abstract][Full Text] [Related]
14. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D
Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth.
Liu XQ; Xiong MH; Shu XT; Tang RZ; Wang J
Mol Pharm; 2012 Oct; 9(10):2863-74. PubMed ID: 22924580
[TBL] [Abstract][Full Text] [Related]
16. Effects of the silencing of hypoxia-inducible Factor-1 alpha on metastasis of pancreatic cancer.
Wei H; Li F; Fu P; Liu X
Eur Rev Med Pharmacol Sci; 2013 Feb; 17(4):436-46. PubMed ID: 23467940
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.
Zhang Y; Ma Y; Lu HP; Gao JH; Liang CS; Liu CZ; Zou JT; Wang HQ
Chin Med J (Engl); 2008 Nov; 121(22):2284-9. PubMed ID: 19080333
[TBL] [Abstract][Full Text] [Related]
18. Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia.
Banham AH; Boddy J; Launchbury R; Han C; Turley H; Malone PR; Harris AL; Fox SB
Prostate; 2007 Jul; 67(10):1091-8. PubMed ID: 17477366
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic investigation and implications of photodynamic therapy induction of vascular endothelial growth factor in prostate cancer.
Solban N; Selbo PK; Sinha AK; Chang SK; Hasan T
Cancer Res; 2006 Jun; 66(11):5633-40. PubMed ID: 16740700
[TBL] [Abstract][Full Text] [Related]
20. [Inhibitory effect of silencing STAT3 gene with short hairpin RNA mediated by polyamidoamine dendrimers on growth of prostate cancer].
Zhao WM; Xiu YC; Xu Y; Wang YM; Cheng ZK; Yu Q; Kong DL
Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):575-9. PubMed ID: 18210874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
